Nls Pharmaceutics Ltd (NLSP) has released an update.
NLS Pharmaceutics Ltd. has acquired an exclusive global license for a novel platform of dual orexin receptor agonists from Aexon Labs, showing promise in treating a range of neurologic and hypersomnolence disorders, including narcolepsy. These next-generation compounds, which include over 300 variations, offer potential advancements in sleep medicine and neurodegenerative diseases by targeting multiple pathways. The company plans to integrate these compounds into its existing pipeline, aiming to provide comprehensive treatment options and enhance shareholder value.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
